Immunomedics, Inc. (NASDAQ:IMMU)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

IMMU News and Commentary

Caps

How do you think IMMU will perform against the market?

Add Stock to CAPS Watchlist

All Players

218 Outperform
23 Underperform
 

All-Star Players

27 Outperform
6 Underperform
 

Wall Street

7 Outperform
1 Underperform
 

Top IMMU Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

NeroSagetrade (81.25)
Submitted October 13, 2007

This is my one...my ONE feel good story in my CAPS portfolio. I've followed Immunomedics for roughly six years and I've liked the direction management has taken the company in each successive year. They have never tried to mislead investors or the… More

zzlangerhans (99.80)
Submitted November 24, 2016

Surprisingly, my recent long bet on Immunomedics turned out to be a winner. Perhaps I have Trump to thank for that since I bought in shortly before the election surprise. Or perhaps I just got lucky: I've made a dozen bottom feeding picks in the last… More

IMMU VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about IMMU.

Recs

0
Member Avatar SaintCroix (98.98) Submitted: 12/14/2017 9:45:58 PM : Outperform Start Price: $12.58 IMMU Score: +29.09

There are no drugs for triple negative breast cancer. IMMU has one, and it did so well in it's phase 2 trial, the FDA is fast-tracking the drug and it will be submitted in first quarter 2018. It's a multi-billion dollar market and IMMU's drug is far more effective than existing therapies. Pretty much a lock, I think. We will see!

Recs

0
Member Avatar tj726 (46.23) Submitted: 10/29/2017 5:13:08 PM : Outperform Start Price: $11.67 IMMU Score: +35.96

success of new drug, new board, buyout/partner potential

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 11/24/2016 5:24:20 PM : Underperform Start Price: $3.53 IMMU Score: -345.92

Surprisingly, my recent long bet on Immunomedics turned out to be a winner. Perhaps I have Trump to thank for that since I bought in shortly before the election surprise. Or perhaps I just got lucky: I've made a dozen bottom feeding picks in the last couple of months and not of all them can plunge straight down, I suppose. My bull thesis on Immunomedics was that the stock would rocket upward once the company initiated the phase III trial of sacituzumab for triple negative breast cancer and simultaneously filed for accelerated approval. I hoped this would happen around the end of 2016. Instead, Immunomedics recently announced that they wouldn't be initiating the trial until mid 2017, which I anticipate eventually will be narrowed down to Q3 2017 and then more than likely postponed to Q4 2017. Even if they remain on the current schedule, there's a strong likelihood of another below market dilutive financing with warrants before any positive catalyst. The last financing crushed the stock well below the offering price. Another bearish factor is that the share price is approaching the warrant exercise price of 3.75, which could lead to further dilution. I wouldn't short Immunomedics yet, but I was glad to liquidate my long position for a healthy profit and I'll be watching any rise over the warrant exercise price with great interest.

Leaderboard

Find the members with the highest scoring picks in IMMU.

Score Leader

GyroDynasty

GyroDynasty (< 20) Score: +923.45

The Score Leader is the player with the highest score across all their picks in IMMU.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
GyroDynasty < 20 9/29/2015 Outperform 5Y $1.57 +954.69% +44.64% +910.05 0 Comment
wmtworker 76.03 8/3/2015 Outperform 5Y $2.05 +707.74% +29.39% +678.35 0 Comment
bibbes < 20 8/3/2015 Outperform 5Y $2.05 +707.74% +29.39% +678.35 0 Comment
pavlos1971 98.73 8/3/2015 Outperform 5Y $2.05 +707.74% +29.39% +678.35 0 Comment
2st2 95.12 1/8/2009 Outperform NS $1.75 +846.21% +207.48% +638.72 0 Comment
2st4 98.44 1/8/2009 Outperform NS $1.75 +846.21% +207.94% +638.26 0 Comment
beemer330 74.15 7/14/2016 Outperform 1Y $2.21 +649.26% +25.94% +623.32 0 Comment
lgrunner34 35.08 10/18/2016 Outperform 5Y $2.23 +642.54% +27.19% +615.35 0 Comment
hmcnamee < 20 5/12/2009 Outperform 1Y $1.81 +814.84% +200.29% +614.55 1 Comment
mikolabruce 31.18 10/10/2006 Outperform 3M $2.00 +719.00% +112.09% +606.91 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackchardan 35.92 1/8/2014 Outperform NS $5.02 +229.85% +48.44% +181.41 0 Comment
TrackJimCramer 85.48 8/15/2013 Underperform 3W $5.11 +224.04% +63.67% -160.38 0 Comment
TrackUltraLong < 20 1/23/2013 Outperform NS $2.91 +469.02% +82.60% +386.42 1 Comment
tracksummerstree 86.41 8/31/2011 Outperform NS $4.00 +313.96% +122.37% +191.60 0 Comment
TrackOppenheimer 71.45 5/17/2011 Outperform NS $3.77 +339.22% +105.22% +234.00 0 Comment
TrackWedbush 88.91 2/23/2011 Outperform NS $3.36 +392.82% +107.89% +284.93 0 Comment
TrackJGreenblatt 63.67 2/16/2010 Outperform 1Y $3.05 +21.31% +22.15% -0.84 2/28/2011 @ $3.70 1 Comment
TrackBreanMurray 76.89 7/3/2007 Outperform NS $4.32 +283.30% +88.36% +194.94 0 Comment
TrackLazardCapit 83.16 2/20/2007 Outperform NS $4.76 +247.87% +98.80% +149.07 0 Comment

Featured Broker Partners